Literature DB >> 9741429

New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

F J Fallaux1, A Bout, I van der Velde, D J van den Wollenberg, K M Hehir, J Keegan, C Auger, S J Cramer, H van Ormondt, A J van der Eb, D Valerio, R C Hoeben.   

Abstract

The presence of replication-competent adenoviruses (RCAs) in batches of replication-defective adenovirus (Ad) vectors is a major problem for the application of these vectors in gene therapy. RCAs are generated by recombination between sequences in the Ad vector and homologous Ad sequences in the helper cells, resulting in the acquisition by the vector of early region 1. To prevent the formation of RCAs, we have developed helper cell lines, which we named PER, and matched Ad vectors that do not have sequence overlap. PER cells contain the Ad serotype 5 (Ad5) E1A- and E1B-encoding sequences (Ad5 nucleotides 459-3510) under the control of the human phosphoglycerate kinase (PGK) promoter. We demonstrate that PER cells synthesize high levels of the Ad5 E1A and E1B proteins. The yields from PER cells of E1-deleted Ads are similar to those obtained from earlier helper cells, such as 911 and 293 cells. Propagation of matched Ad vectors, which lack Ad5 nucleotides 459-3510, in one of the PER clones, PER.C6, does not result in the generation of RCAs, in contrast to propagation in 293 cells. We conclude that the combination of PER.C6 cells and nonoverlapping E1-deleted adenoviral vectors eliminates the problem of RCA generation by homologous recombination, and allows cost-effective production of safe, clinical-grade batches of recombinant Ad vectors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741429     DOI: 10.1089/hum.1998.9.13-1909

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  97 in total

1.  Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization.

Authors:  M Rosa-Calatrava; L Grave; F Puvion-Dutilleul; B Chatton; C Kedinger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  General strategy for broadening adenovirus tropism.

Authors:  Laura Fontana; Maurizio Nuzzo; Lorena Urbanelli; Paolo Monaci
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches.

Authors:  Pete Murakami; Menzo Havenga; Farah Fawaz; Ronald Vogels; Giuseppe Marzio; Erno Pungor; Jim Files; Linh Do; Jaap Goudsmit; Michael McCaman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Authors:  Lennart Holterman; Ronald Vogels; Remko van der Vlugt; Martijn Sieuwerts; Jos Grimbergen; Jorn Kaspers; Eric Geelen; Esmeralda van der Helm; Angelique Lemckert; Gert Gillissen; Sandra Verhaagh; Jerome Custers; David Zuijdgeest; Ben Berkhout; Margreet Bakker; Paul Quax; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer.

Authors:  E J Kremer; S Boutin; M Chillon; O Danos
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

10.  The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35.

Authors:  Christoph Fleischli; Sandra Verhaagh; Menzo Havenga; Dominique Sirena; Walter Schaffner; Roberto Cattaneo; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.